Clinical Trial Update: Study Evaluating ReFacto in Hemophilia A [NA]

View source ↗

Summary

A clinical trial evaluating ReFacto for Hemophilia A has completed. The sponsor Wyeth is now a wholly owned subsidiary of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Refacto (Factor VIII, recombinant)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Hemophilia A | NA | Status: COMPLETED